Ascendis Pharma doubles sales expenses ahead of product launch

Preparations for Skytrofa's launch in mid-October has meant one particular cost item has skyrocketed for Ascendis, which is now in the process of convincing doctors, patients and health insurers of the benefits of a weekly administration in growth hormone treatment compared to a daily drug.

Photo: Kevin Grønnemann / MedWatch

The market will have to wait a little longer before new sales figures arrive from Acendis Pharma's newly approved growth hormone treatment Skytrofa, as the drug was only launched a few weeks into the fourth quarter.

Before then, however, Ascendis has evidently been keeping busy relating to the launch, according to the company's third quarter financial report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs